Madison Vaccines Incorporated said Monday the company has closed on $8 million in financing to move forward with its therapies for prostate cancer.
MVI is working on two vaccines to combat prostate cancer, one of which is in Phase 2 clinical trials. The technology was developed in the lab of UW-Madison medical school professor Douglas McNeel.
